The European Union approved Shering-Plough's Bridion (sugammadex) in an injection form for the purposes of reversing neuromuscular blockade during general anesthesia more rapidly. This will be the first product approval since Schering-Plough joined forces with Organon BioSciences. Release [1]
Links:
[1] http://www.fiercebiotech.com/press-releases/bridion-r-sugammadex-injection-first-and-only-selective-relaxant-binding-agent-appr-0
[2] http://www.marketwatch.com/news/story/bridionr-sugammadex-injection---first/story.aspx?guid=%7BBEC35410-79F9-4B94-8E52-A4DC6EABB941%7D&dist=hppr